159
Views
5
CrossRef citations to date
0
Altmetric
Short Report

The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma–COPD Overlap Syndrome

ORCID Icon, ORCID Icon, , ORCID Icon, , , , , , , ORCID Icon, & show all
Pages 363-369 | Published online: 18 Mar 2022

References

  • Pérez de Llano L, Miravitlles M, Golpe R, et al. A proposed approach to Chronic Airway Disease (CAD) using therapeutic goals and treatable traits: a look to the future. Int J Chron Obstruct Pulmon Dis. 2020;15:2091–2100. doi:10.2147/COPD.S263430
  • Hashimoto S, Sorimachi R, Jinnai T, Ichinose M. Asthma and chronic obstructive pulmonary disease overlap according to the Japanese Respiratory Society Diagnostic Criteria: the Prospective, Observational ACO Japan Cohort Study. Adv Ther. 2021;38(2):1168–1184. doi:10.1007/s12325-020-01573-x
  • Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023–1042. doi:10.1111/all.14221
  • Global initiative for asthma. Available from: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf. Accessed March 13, 2021.
  • Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113(1):59–65. doi:10.1016/j.jaci.2003.09.008
  • Hanania NA, Chipps BE, Griffin NM, Yoo B, Iqbal A, Casale TB. Omalizumab effectiveness in asthma-COPD overlap: post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019;143(4):1629–1633.e2. doi:10.1016/j.jaci.2018.11.032
  • Eger K, Kroes JA, Ten Brinke A, Bel EH. Long-term therapy response to anti-IL-5 biologics in severe asthma-a real-life evaluation. J Allergy Clin Immunol Pract. 2021;9(3):1194–1200. doi:10.1016/j.jaip.2020.10.010
  • Donovan T, Milan SJ, Wang R, Banchoff E, Bradley P, Crossingham I. Anti-IL-5 therapies for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2020;12:CD013432. doi:10.1002/14651858.CD013432.pub2
  • Maltby S, Gibson PG, Powell H, McDonald VM. Omalizumab treatment response in a population with severe allergic asthma and overlapping COPD. Chest. 2017;151(1):78–89. doi:10.1016/j.chest.2016.09.035